You can now read 10 articles each month for free on BostonGlobe.com.

The Boston Globe

Business

FDA OK’s breast cancer drug created in part by ImmunoGen

Federal regulators approved a highly anticipated breast cancer drug Friday, two and a half years after they sparked patient protests by refusing to grant it a speedy review.

The drug, which will be sold under the brand name Kadcyla, is considered a breakthrough treatment because it deploys a potent toxin that combines with an existing drug, Herceptin, to kill breast cancer cells. It could initially benefit as many as 15,000 patients who have a particularly aggressive form of the disease.

Loading comments...

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week